Moss Report on Ovarian Cancer
Alternative & Conventional Ovarian Cancer Treatments
Ovarian Cancer Treatment
The Moss Report on Ovarian Cancer begins with a discussion of conventional oncology’s understanding and treatment of this major form of cancer. This includes such topics as surgery, radiation therapy, chemotherapy, immunotherapy, hormone treatment, targeted therapy, and other new treatments.
It discusses markers used to detect the existence and progression of the disease, and useful methods for determining whether or not a patient will benefit appreciably from various treatments. The main body of this Moss Report contains comprehensive, up-to-date information on conventional, integrative, experimental, complementary, CAM, dietary, and alternative cancer treatments and other matters of urgent concern to ovarian cancer patients.
We also discuss innovative and alternative treatment centers for treating ovarian cancer, in the US and abroad.
This 492-page report features a comprehensive discussion of the treatment and prevention of this cancer – from the best techniques of surgery, radiation and chemotherapy to the latest complementary and alternative (CAM) approaches. New this year is a discussion of how science is harnessing the immune system to fight cancer. This includes encouraging preliminary results with immune checkpoint inhibitors and adoptive immunotherapy. There is a discussion of the new drug niraparib for platinum-sensitive, recurrent ovarian cancer, which is causing an improvement progression-free survival (PFS) in this disease. There is also an up-to-the-minute discussion of a form of hyperthermia (or heat therapy) called Oncothermia.
What’s New In Ovarian Cancer Treatment
New studies on fertility preservation with cryopreserved ovarian tissue transplantation (OTT).
James Allison, PhD, is the head of immunology at the University of Texas M.D. Anderson Cancer Center, Houston. While at the University of California, Berkeley, he invented an important new class of medications called “immune checkpoint inhibitors.” Allison is currently working on combining these medications with cancer-killing viruses, such as Newcastle Disease Virus (NDV) vaccines. These are already available at several foreign clinics. One of the most significant advances of recent years has been the development and FDA approval of an anti-cancer virus vaccine, Reolysin® (pelareorep). This Moss Report discusses this new medicine and its associated clinical trials.
No patient with ovarian cancer should be without this outstanding resource.
Discounts and Savings Available
Purchase both the E-Book and
Printed Moss Report and save $100.*
Purchase a Moss Report and
Schedule a Consultation and save $100.*
If you are a Medical Professional and refer patients to Moss Reports, click here find out more about our advocate program.
*Discounts applied when purchased together at check-out.
“I can’t tell you what a wealth of information we found and how helpful and informative the Report was. Thank you. My eyes were truly opened.” — L. C.
“Thank you very much. Your report is very helpful and comprehensive.” —B. S.
“We have received your report.. and sincerely appreciate your thoroughness and writing style.” —R. D.
“I have really been disappointed with radiation and chemotherapy and have been so glad that you steered me to more viable alternatives.” —W. V.
“Thanks for your help. Your service is a marvelous resource, tremendously helpful for those of us sifting through the masses of information that we have to go through in these really stressful situations.” — S. A.
Table of Contents
- A QUICK GUIDE TO CAM CANCER TREATMENTS
- GREEN LIGHT TREATMENTS: WELL RESEARCHED APPROACHES
- AMBER LIGHT TREATMENTS FOR CANCER: EFFICACY AND SAFETY STILL UNCLEAR
- RED LIGHT TREATMENTS: POORLY RESEARCHED (OR DOWNRIGHT DANGEROUS)
- CONVENTIONAL TREATMENT SECTION
- GENERAL CONSIDERATIONS
- DIAGNOSIS OF OVARIAN CANCER
- HUMAN EPIDIDYMIS PROTEIN 4 (HE4)
- OVA1 TESTING
- TREATMENT OVERVIEW
- STAGES AND GRADES
- CHEMOTHERAPY OF OVARIAN CANCER
- FDA APPROVED SINGLE AGENTS FOR OVARIAN CANCER
- FDA-APPROVED DRUG COMBINATIONS
- NCCN RECOMMENDATIONS
- TREATMENT OF STAGE IA AND IB
- TREATMENT OF STAGE IIA
- INTRAPERITONEAL CHEMOTHERAPY
- STAGES II, III AND IV POST-PRIMARY TREATMENT
- SECOND LOOK SURGERY (SLL)
- TREATMENT OF RECURRENT DISEASE
- NIRAPARIB FOR RECURRENT OVARIAN CANCER
- TAMOXIFEN AND OVARIAN CANCER
- BETA-BLOCKERS AND OVARIAN CANCER SURVIVAL
- MELATONIN AND CHEMOTHERAPY
- IMMUNE CHECKPOINT BLOCKADE (ICB)
- ADOPTIVE IMMUNOTHERAPY (CAR-T CELL)
- SPECIFIC NATURAL AGENTS FOR OVARIAN CANCER
- FWGE AND OVARIAN CANCER
- METFORMIN AND OVARIAN CANCER
- SOY AND GYNECOLOGICAL CANCERS
- ROLE OF ONCOTHERMIA IN GYNECOLOGIC CANCER: EXPERIENCES
- TOP SUPPLEMENTS (THE SHORT LIST)
- ANTI-CANCER PLAN ON A TIGHT BUDGET
- ANTI-CANCER RECIPES
- THE HALLMARKS OF CANCER
- A NEW MODEL FOR CANCER TREATMENT
- INNOVATIVE SURGERY
- INNOVATIVE RADIATION THERAPY
- INNOVATIVE CHEMOTHERAPY
- NAUSEA AND VOMITING
- MOUTH SORES (STOMATITIS)
- ZINC SULFATE
- NERVE PAIN
- HAIR LOSS
- PICKLE JUICE REMEDY
- CHEMOSENSITIVITY TESTING
- TARGETED THERAPIES
- PRECISION MEDICINE INITIATIVE
- ANTI-ANGIOGENESIS DRUGS
- MOLECULAR AND GENOMIC TESTING
- CIRCULATING TUMOR CELLS (CELLSEARCH)
- MONOCLONAL ANTIBODIES
- IMMUNE CHECKPOINT BLOCKADE (ICB)
- CANCER STEM CELLS (CSCS)
- DIETARY COMPOUNDS THAT KILL CANCER STEM CELLS (CSCS)
- PHYSICAL ACTIVITY AND EXERCISE
- FASTING AND THE KETOGENIC DIET
- A COST-FREE WAY TO PREVENT CANCER RECURRENCES
- CALORIC RESTRICTION
- PRACTICAL NOTES ON FASTING
- TOP TEN SUPPLEMENTS (THE EXPOSITION)
- FOOD AND CANCER PREVENTION
- VITAMINS, MINERALS & ANTIOXIDANTS
- THE CONCURRENT USE DEBATE
- CONCURRENT USE OF ANTIOXIDANTS AND RADIATION
- HERBS, SPICES AND BOTANICALS
- SOUND, LIGHT AND ELECTRICITY
- CANCER IMMUNOTHERAPY
- VIRAL THERAPY (ONCOLYTIC VIRUSES)
- DRUGS NEW AND OLD
- INNOVATIVE CANCER CLINICS
- FINDING AN INTEGRATIVE PHYSICIAN
- INTEGRATIVE ONCOLOGY DEPARTMENTS
- AMERICAN CLINICS
- INTERNATIONAL CLINICSSUPPLEMENTS AND SURGERY
- CAM AND FATIGUE
- POPULAR BUT UNLIKELY TREATMENTS